SMi's 9th Annual Conference: Biobanking 2019

SMi Group25 - 26 September 2019, London, UK.
With the estimated revenues of the global biobanking industry reaching US$ 27.54 billion in 2020, backed by an explosive CAGR of 9.5% between now and 2026. This market growth is fuelled by the increasing drive towards precision and personalised medicine and thus, quality biosamples are now in soaring demand.

Come join Biobanking 2019 in September 2019 and; thoroughly understand the latest developments in the biobanking industry; network with the industry experts and key opinion leaders; gain insight into how the biobanking industry at the forefront at driving precision medicine and enhancing research and discover 'Drone4Care', how drone delivery of biosamples can be a reality.

The event will bring together internationally recognised biorepositories, scientific pioneers from pharmaceutical companies, and academics to strengthen current knowledge in biosample management and their research applications. We will cover the most relevant hot topics including: the latest biorepository technological breakthroughs, the best practices in biobanking, shifts in the biosample regulation landscape, the international biobank societies with ESBB and ISBER, along with a whole host of successful biobanking business model structures to help reinvigorate your biobank.

Benefits of attending

  • Discover 'Drone4care' from Laurent Dollé, the innovative and daring plan to use drones for the delivery of biomaterial. Additionally, he will be detailing the new promising technology of Tissue Microarray, a bioprocessing technology that can reduced the number of needed biosamples for research from 200 down to 1
  • Hear from UK Biobank on the continual impact of GDPR on the biobanking landscape
  • Learn about a diverse range of the most successful biobanking business models from real case studies
  • Gain insight from the global biobank collaboration societies of ESBB and ISBER, see how you can place your biobank on the international stage

For further information and to register, please visit:
http://www.biobanking-event.com/wpnwl

Early bird rates

  • Book by 30th April and save £400
  • Book by 31st May and save £300
  • Book by the 28th June and save £200

Plus, two interactive half day pre-conference workshops:

Workshop A: Reinvigorate your through data quality enhancement and Financial and Economic tools
Workshop Leader:Laurent Dollé, Managing Director, BWB (BiothèqueWallonieBruxelles)
8:30 - 12:30

Workshop B: The Organic Development of a Sustainable Academic Biobank
Workshop Leader:Mary-Beth Joshi, Director, Biobank & translational Research Core, Duke University Medical Centre
1:30 - 5:30

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...